GlassScriptPhysician profile
Michelle Lee Caro
NPI 1548039423
$1,114.78
in general payments reported to CMS, 2019-2025
17 companies · $277 in 2025
The $277 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $838 · 2025: $277.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,098 · Education: $16.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,097.87 |
| Education | $16.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $287.13 | 2024 | Voquezna |
| Abbvie INC. | $273.76 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $90.42 | 2024-2025 | Dupixent |
| Genzyme Corporation | $73.02 | 2024-2025 | |
| Ardelyx, INC. | $70.16 | 2024 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $44.60 | 2024-2025 | |
| Janssen Biotech, INC. | $39.36 | 2025 | Tremfya |
| Qol Medical, LLC | $38.39 | 2025 | Sucraid |
| Vivus LLC | $35.69 | 2024 | Qsymia |
| Madrigal Pharmaceuticals | $32.68 | 2025 | Rezdiffra |
| Braintree Laboratories, INC. | $23.14 | 2025 | Sutab, Suflave |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.62 | 2024 | Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $18.16 | 2024 | Entyvio |
| Ironwood Pharmaceuticals, INC | $17.55 | 2025 | |
| Celltrion USA INC. | $16.91 | 2024 | Zymfentra |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axogen | $16.70 | 2025 | |
| Ferring Pharmaceuticals INC. | $16.49 | 2024 | Rebyota |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Caro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.